Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    10,212 result(s) found for: cancer. Displaying page 198 of 511.
    «« First « Previous 194  195  196  197  198  199  200  201  202  Next» Last»»
    EudraCT Number: 2011-005638-20 Sponsor Protocol Number: CRO-2010-14 Start Date*: 2011-02-18
    Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
    Full Title: Phase III randomized trial of preoperative radiotherapy with an integrated simultaneous boost IMRT-IGRT) versus chemoradiotherapy for T3-4 rectal cancer
    Medical condition: Patients with operable rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062099 Rectal neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000150-26 Sponsor Protocol Number: POLESTAR Start Date*: 2022-02-14
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH
    Full Title: Phase IIA trial of short-term chemotherapy and pembrolizumab, followed by Pembrolizumab and Olaparib as firstline therapy in Her-2 negative gastric/gastroesophageal-junction (GEJ) Adenocarcinoma – ...
    Medical condition: metastatic or advanced inoperable Her-2 negative esophagogastric adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004076-13 Sponsor Protocol Number: 5 Start Date*: 2006-11-28
    Sponsor Name:Huvud- hals- lung- och hudcancer, Tema Cancer Karolinska Universitetssjukhuset
    Full Title: Secar I Part I: A study of MTD of Sodium selenite in patients with advanced carcinoma. A phase I study. Amendment 5: continuous treatment
    Medical condition: Patients with stage III or IV cancer in whom first and second line treatment have been given but who have tumours that are still progressing, giving symptomes. The patients must be in a fairly good...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003765-10 Sponsor Protocol Number: I-Tackle Start Date*: 2018-07-10
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance
    Medical condition: Patient with Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002651-28 Sponsor Protocol Number: IRST185.05 Start Date*: 2018-02-22
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Multi-cohort investigational study to evaluate the impact of pelvic mp-3TMRI and whole-body 68Ga-PSMA PET/CT for diagnosis of clinically-significant prostate cancer and pre-surgical staging.
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001186 Adenocarcinoma of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004623-36 Sponsor Protocol Number: MEGALiT1901 Start Date*: 2019-11-29
    Sponsor Name:Uppsala University Hospital
    Full Title: A MolEcularly Guided Anti-Cancer Drug Off-Label Trial – a multicenter, basket and umbrella explorative trial on the efficacy and safety of molecular profile selected commercially available targete...
    Medical condition: In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002246-68 Sponsor Protocol Number: DUTRENEO Start Date*: 2018-09-06
    Sponsor Name:Fundación CRIS contra el cancer
    Full Title: The DUTRENEO Trial: A Prospective Study to Individualize the Approach with DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer patients.
    Medical condition: The study aims to evaluate the activity of cisplatin based neoadjuvant chemotherapy compared with the combination of durvalumab and tremelimumab to T2-T4a bladder cancer patients according to the p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-006994-48 Sponsor Protocol Number: EMPATICC-INCOR1 Start Date*: 2022-07-25
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Empower the Heart of Patients with Terminal Cancer using Cardiac Medicines Trial
    Medical condition: Patients with terminal cancer in palliative care
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10059513 Palliative care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002429-12 Sponsor Protocol Number: UC_0160/1613 Start Date*: 2018-01-31
    Sponsor Name:UNICANCER
    Full Title: PERSONALIZED TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS ACCORDING TO CIRCULATING TUMOR CELLS KINETIC DURING CHEMOTHERAPY
    Medical condition: Metastatic castrate-resistant prostate cancer requiring initiation of chemotherapy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001105-85 Sponsor Protocol Number: P_2017_007 Start Date*: 2018-06-12
    Sponsor Name:Centre Hospitalier Annecy Genevois
    Full Title: A multicenter phase II study evaluating denosumab (XGEVA®) in combination with nivolumab (OPDIVO®) as second-line therapy for patients with stage IV non-small–cell lung cancer (squamous and non-squ...
    Medical condition: second-line therapy for patients with stage IV non-small cell lung cancer (squamous and non-squamous) with bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000105-20 Sponsor Protocol Number: 0316-ASG Start Date*: 2017-10-02
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Neoadjuvant anti PD-1 immunotherapy in resectable non-small cell lung cancer
    Medical condition: non-small cell lung cancer (NSCLC), resectable
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001103-35 Sponsor Protocol Number: NSGO -EC - 0302 Start Date*: 2004-08-20
    Sponsor Name:Nordic Society for Gynecologic Oncology
    Full Title: Exemestane in Advanced or Recurrent Endometrial Carcinoma. A multicentre non-randomized Phase II study
    Medical condition: Advanced or recurrent endometrial carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001240-25 Sponsor Protocol Number: MOURO48 Start Date*: Information not available in EudraCT
    Sponsor Name:Radboudumc
    Full Title: Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer
    Medical condition: (metastatic) castration-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005376-34 Sponsor Protocol Number: BEV-ONCO2012 Start Date*: 2012-12-20
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Randomized Phase 2 study comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab with FOLFOX or FOLFIRI.
    Medical condition: Resecable Metastatic Cororectal Cancer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-004115-92 Sponsor Protocol Number: 1944/2022 Start Date*: 2023-11-14
    Sponsor Name:Medical University of Vienna
    Full Title: Neoadjuvant [177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA-11 PET imaging followed by radical prostatectomy: A Pros...
    Medical condition: Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-001752-35 Sponsor Protocol Number: 2018-06 Start Date*: 2019-11-21
    Sponsor Name:Centre Oscar Lambret
    Full Title: Phase II trial of weekly Carboplatin-Paclitaxel adjuvant chemotherapy after intensity modulated extended-field chemoradiation in the treatment of locally advanced cervical cancer with para-aortic p...
    Medical condition: Patients treated for a cervical cancer locally advanced presenting positive lombo-aortic lymph nodes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004336-31 Sponsor Protocol Number: D4194C00009 Start Date*: 2020-08-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemoth...
    Medical condition: Patients with Stage III unresectable Non-small cell lung cancer (NSCLC), who have an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2 and who are treated with radiotherapy but are ineligible ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000319-26 Sponsor Protocol Number: CLDK378A2301 Start Date*: 2013-08-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-s...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Prematurely Ended) IT (Completed) NL (Prematurely Ended) DE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) GR (Completed) HU (Completed) IE (Prematurely Ended) PL (Prematurely Ended) DK (Completed) NO (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001173-14 Sponsor Protocol Number: H3E-MC-JMHO Start Date*: 2006-07-17
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomised Phase 3 Trial of Alimta (pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer.
    Medical condition: Extensive stage Disease Small cell Lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) ES (Completed) HU (Completed) PT (Prematurely Ended) GR (Prematurely Ended) NL (Completed) AT (Prematurely Ended) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001408-23 Sponsor Protocol Number: ABI-007-PANC-007 Start Date*: 2015-03-05
    Sponsor Name:Celgene Corporation
    Full Title: NAB-PACLITAXEL (ABRAXANE®) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE 2 STUDY (LAPACT)
    Medical condition: Locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 194  195  196  197  198  199  200  201  202  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 08:28:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA